Skip to content

Clinical trials

Observational Glioma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glioma Phase: Observational Clear all

276 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20021
20034
20047
20054
20066
20072
20084
20095
20107
20115
20128
20135
201414
201511
201617
201714
201814
201913
202010
202115
202227
202322
202421
202514
202617

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed110
Recruiting61
Unknown status57
Terminated16
Not yet recruiting15
Active, not recruiting10
Withdrawn5
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)9
The First Affiliated Hospital of Zhengzhou University7
Huashan Hospital6
National Institute of Neurological Disorders and Stroke (NINDS)6
AHS Cancer Control Alberta5
Deep Learning Institute of Radiological Sciences5
M.D. Anderson Cancer Center4
Maastricht Radiation Oncology4
Tata Memorial Centre4
University Hospital, Montpellier4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glioma276
Brain Neoplasms69
Glioblastoma65
Astrocytoma43
Oligodendroglioma20
Central Nervous System Neoplasms16
Ependymoma16
Medulloblastoma14
Neoplasms14
Disease10

Trials

Showing 1 to 25 of 276. Each trial links to its page on Pharma Observatory.

176 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.